Global Markets for Bioengineered Protein Drugs

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,500	185 Pages	BCC Research	March, 2023	WA17812480

Best Price Guarantee
Price	from $5,500
Length	185 Pages
Publisher	BCC Research
Published Date	March, 2023
SKU	WA17812480

Global Markets for Bioengineered Protein Drugs

Report Scope:

This report aims to provide a comprehensive study of the global market for bioengineered protein drugs, both in terms of quantitative and qualitative data, to help readers develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions regarding bioengineered protein drugs. Segmentation is based on the drug type, disease type, and region.

Industry growth drivers, restraints, trends, and opportunities in bioengineered protein drugs are also discussed in detail. The report also provides information on the bioengineered protein drug market competitive landscape, features detailed company profiles, and discusses the impact of COVID-19 on the market.

Report Includes:

28 data tables and 23 additional tables

An up-to-date overview and analysis of the global markets for bioengineered protein drugs

Analyses of the global market trends, with historic market revenue data (sales figures) from 2019-2021, estimates for 2022, forecasts for 2023, and projections of compound annual growth rates (CAGRs) through 2027

Highlights of the emerging technology trends, opportunities and gaps estimating current and future demand for bioengineered protein drugs market, and major regions and countries involved in market developments

Estimation of the actual market size and revenue forecast for global bioengineered protein drugs market in USD million terms, and corresponding market share analysis by drug type, disease type, and region

In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall biopharmaceutical industry

Discussion of the regulatory aspects and standards for bioengineered protein therapeutics, newly approved products, underlying clinical trials for all phases and list of vaccines, and the COVID-19 impact on the progress of this market

Insight into the recent industry structure, competitive aspects of each product segment, increasing investment on R&D activities to develop new and improved therapies, market development strategies, and company value share analysis

Identification of the major companies involved in the production and modification of protein drugs, and analysis of the company competitive landscape based on their recent developments, financial performance, and segmental revenues

Descriptive company profiles of the leading global players, including AbbVie Inc., AstraZeneca plc, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) Co., Pfizer Inc., Merck and Co., and Sanofi S.A.

Companies Mentioned

ABBVIE INC.
ADMA BIOLOGICS INC.
AMGEN INC.
ASTRAZENECA PLC
BAYER PHARMACEUTICALS
BioNTech SE
BRISTOL-MYERS SQUIBB
CSL LTD.
ELI LILLY AND CO.
F. Hoffmann-La Roche AG
GLAXOSMITHKLINE PLC
GRIFOLS S.A.
JOHNSON & JOHNSON
MERCK & CO., INC.
NOVARTIS AG
NOVO NORDISK A/S
OCTAPHARMA AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO., LTD.

Chapter 1 Introduction: 1.1 Study Goals and Objectives; 1.2 Scope of This Report; 1.3 Methodology and Information Sources; 1.4 What's New in This Update?; 1.5 Geographic Breakdown; 1.6 Analyst's Credentials; 1.7 BCC Custom Research; 1.8 Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background: 3.1 Protein Drugs Overview; 3.2 Bioengineered Protein Drugs; 3.3 Manufacturing Technologies; 3.3.1 Fractionation/Extraction from Natural Sources (Human/Animal); 3.3.2 Microbial Fermentation and Bioreactors; 3.3.3 Transgenics; 3.3.4 Mammalian Cell Culture
Chapter 4 Market Dynamics: 4.1 Market Drivers; 4.1.1 Growing and Aging Population; 4.1.2 Increasing Prevalence of Chronic Diseases; 4.1.3 Advancements in Manufacturing Technologies; 4.1.4 New Product Launches and Label Expansions; 4.1.5 Premium Pricing; 4.1.6 Collaborations and Licensing Agreements; 4.2 Market Challenges; 4.2.1 Evolving Regulatory Scenario; 4.2.2 Accelerating Biosimilars Market
Chapter 5 Market Breakdown by Drug Type: 5.1 Overview; 5.2 Monoclonal Antibodies (mAbs); 5.2.1 Types of mAbs; 5.3 Peptide Hormones; 5.3.1 Types of Peptide Hormones; 5.4 Vaccines; 5.4.1 Types of Vaccines; 5.5 Fusion Proteins; 5.5.1 Types of Fusion Proteins; 5.6 Blood Factors; 5.6.1 Types of Blood Factors; 5.7 Peptide Antibiotics; 5.7.1 Types of Peptide Antibiotics; 5.8 Cytokines; 5.8.1 Types of Cytokines; 5.9 Therapeutic Enzymes; 5.9.1 Types of Therapeutic Enzymes; 5.10 Global Market for Bioengineered Protein Drugs, by Type; 5.10.1 Monoclonal Antibodies (mAbs); 5.10.2 Peptide Hormones; 5.10.3 Vaccines; 5.10.4 Blood Factors and Peptide Antibiotics; 5.10.5 Fusion Proteins; 5.10.6 Cytokines; 5.10.7 Therapeutic Enzymes
Chapter 6 Market Breakdown by Disease: 6.1 Overview; 6.2 Autoimmune Diseases and Other Immunodeficiency Disorders; 6.3 Solid Tumors; 6.4 Diabetes; 6.4.1 Type 1 Diabetes; 6.4.2 Type 2 Diabetes; 6.4.3 Gestational Diabetes; 6.5 Infectious Diseases; 6.5.1 Pneumococcal; 6.5.2 Diphtheria, Tetanus; 6.5.3 Human Papillomavirus (HPV); 6.5.4 MMR; 6.5.5 Influenza; 6.5.6 Hepatitis A; 6.5.7 Others; 6.6 Blood Disorders; 6.6.1 Bleeding Disorders; 6.6.2 Anemia; 6.6.3 Blood Cancer; 6.6.4 Paroxysmal Nocturnal Hemoglobinuria; 6.7 Growth Hormone Disorders, Enzyme Deficiency Disorders, and Infertility; 6.8 Others; 6.8.1 Osteoporosis; 6.8.2 Asthma; 6.8.3 Eye Disorders and Diseases; 6.8.4 Transplants; 6.8.5 Cardiovascular Diseases; 6.8.6 Respiratory Syncytial Virus Infection; 6.8.7 Skin Diseases; 6.9 Global Market for Bioengineered Protein Drugs, by Disease; 6.9.1 Autoimmune Diseases and Other Immunodeficiency Disorders; 6.9.2 Solid Tumors; 6.9.3 Diabetes; 6.9.4 Infectious Diseases; 6.9.5 Blood Disorders; 6.9.6 Growth Hormone Disorders, Enzyme Disorders, and Infertility; 6.9.7 Others
Chapter 7 Market Breakdown by Region: 7.1 Global Markets for Bioengineered Protein Drugs, by Region; 7.1.1 North America Market Revenue, by Drug Type; 7.1.2 Europe Market Revenue, by Drug Type; 7.1.3 Emerging Markets Revenue, by Drug Type
Chapter 8 Regulatory Aspects and New Approvals: 8.1 New Approvals; 8.1.1 Monoclonal Antibodies (mAbs); 8.1.2 Peptide Hormones; 8.1.3 Vaccines; 8.1.4 Blood factors; 8.1.5 Peptide Antibiotics; 8.1.6 Therapeutic Enzymes; 8.1.7 Cytokines; 8.1.8 Fusion Protein
Chapter 9 Competitive Landscape: 9.1 Overview; 9.2 Blockbuster Bioengineered Protein Pharmaceutical Brands; 9.3 Monoclonal Antibodies; 9.3.1 Market Share; 9.3.2 Ten Top-Selling Monoclonal Antibodies; 9.4 Peptide Hormones; 9.4.1 Market Share; 9.5 Vaccines (Excluding COVID-19); 9.5.1 Market Share; 9.6 Blood Factors and Peptide Antibiotics; 9.6.1 Key Players in Recombinant Blood Factors Market; 9.6.2 Key players in Peptide Antibiotics Market; 9.7 Fusion Proteins; 9.7.1 Market Share; 9.8 Cytokines; 9.8.1Market Share; 9.9 Therapeutic Enzymes; 9.9.1 Market Share
Chapter 10 Emerging Trends/Upcoming Technologies in the Market: 10.1 Bi- and Multi-Specific Antibodies; 10.1.1 Oral GLP-1 Therapy; 10.1.2 Accelerating Rare Disease Research Worldwide; 10.2 Key Trends in Biopharmaceutical Industry
Chapter 11 Impact of COVID-19 Pandemic: 11.1 Overview; 11.2 Impact on Bioengineered Protein Drugs Market; 11.2.1 Impact on the mAbs Market; 11.2.2 Impact on Peptide Hormone Market; 11.2.3 Impact on Vaccines Market; 11.2.4 Impact on Blood Factors and Peptide Antibiotics Market; 11.2.5 Impact on Fusion Protein Market; 11.2.6 Impact on Cytokines Market; 11.2.7 Impact on Therapeutic Enzyme Market
Chapter 12 Company Profiles: ABBVIE INC.; ADMA BIOLOGICS INC.; AMGEN INC.; ASTRAZENECA PLC; BAYER PHARMACEUTICALS; BIONTECH SE; BRISTOL-MYERS SQUIBB; CSL LTD.; ELI LILLY AND CO.; F. HOFFMANN-LA ROCHE AG; GLAXOSMITHKLINE PLC; GRIFOLS S.A.; JOHNSON & JOHNSON; MERCK & CO., INC.; NOVARTIS AG; NOVO NORDISK A/S; OCTAPHARMA AG; PFIZER INC.; REGENERON PHARMACEUTICALS INC.; SANOFI; TAKEDA PHARMACEUTICAL CO., LTD.